Oral therapy for chronic immune thrombocytopenic purpura

Revolade (eltrombopag) is the first oral treatment option for chronic immune thrombocytopenic purpura to be launched in the UK.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes.

The dosing schedule is dependent on the individual patient's platelet counts but consists of a once daily oral dose.

The objective of treatment with eltrombopag is to maintain platelet counts above the level for haemorrhagic risk (50000/microlitre).

In most patients, measurable elevations in platelet counts take 1-2 weeks.

View Revolade drug record

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Asthma drug hailed as first non-hospital treatment for COVID-19

Asthma drug hailed as first non-hospital treatment for COVID-19

Inhaled budesonide is the first widely available, inexpensive...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Under-30s to be offered alternative to AstraZeneca COVID-19 vaccine after reports of rare blood clots